公开(公告)号：EP4442685A1

公开(公告)日：2024-10-09

申请号：EP22903465.7

申请日：2022-12-06

申请人： Hangzhou HealZen Therapeutics Co., Ltd. ,  Guangdong Hongye Pharmaceutical Co., Ltd.

发明人： LIU, Xingguo ,  SU, Mingbo ,  WU, Yizhe ,  GAO, Anhui ,  ZHOU, Xinglu ,  ZHONG, Li ,  HU, Miao ,  HUANG, Jinglai ,  JING, Hanghui ,  ZHU, Jianrong

IPC分类号： C07D403/12 ,  C07D471/04 ,  C07D498/14 ,  A61K31/496 ,  A61K31/437 ,  A61K31/499 ,  A61P35/00

CPC分类号： Y02P20/55 ,  A61K31/437 ,  A61K31/438 ,  A61K31/496 ,  A61K31/499 ,  A61K31/635 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  C07D403/12 ,  C07D471/04 ,  C07D498/14

摘要： Disclosed is a BCL-2 protein apoptosis inducer, and further disclosed are the uses of the compound and a pharmaceutical composition comprising the compound in the preparation of a drug for treating diseases related to anti-apoptotic protein BCL-2. The compound has potent BCL-2BAK blocking activity, and can be used for treating diseases such as infectious diseases, immune diseases, inflammatory diseases or cell proliferation abnormalities that benefit from the inhibition of anti-apoptotic protein BCL-2.